Citius Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 22
- Market Cap
- $106.9M
- Website
- http://www.citiuspharma.com
- Introduction
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary ...
You need to enable JavaScript to run this app.
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results from Phase I Trial
Citius Pharmaceuticals and Citius Oncology announce preliminary results from a Phase I trial combining pembrolizumab and LYMPHIR in recurrent solid tumors, showing a 27% Objective Response Rate and 33% Clinical Benefit Rate with a median Progression Free Survival of 57 weeks. The chemotherapy-free regimen is well-tolerated with no serious immune-related adverse events.
FDA Approves Lymphir (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
FDA approves Lymphir (denileukin diftitox-cxdl) immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Lymphir targets the interleukin-2 (IL-2) receptor on malignant T-cells and Tregs, offering rapid skin relief without cumulative toxicity. The approval is based on a Phase 3 study showing a 36.2% Objective Response Rate (ORR) with 8.7% achieving Complete Response (CR), and a median time to response of 1.4 months.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath